SCHEMBL4859334

SCHEMBL4859334

Cc1nc(-c2ccc(Cl)cc2)n[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.56
NR1H3 Q13133 2/20 0.56
HDAC3 O15379 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
NCOR2 Q9Y618 1/20 0.56
RET P07949 2/20 0.50
RAB9A P51151 2/20 0.50
EGFR P00533 1/20 0.50
KDR P35968 1/20 0.50
S1PR1 P21453 1/20 0.46
S1PR3 Q99500 1/20 0.46
RPA1 P27694 1/20 0.46
AOC3 Q16853 2/20 0.44
IKBKB O14920 1/20 0.44
MAP3K14 Q99558 1/20 0.44
NPC1 O15118 1/20 0.44
NR1H4 Q96RI1 1/20 0.43
ALPL P05186 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26107873 0.89 HDAC3 (0.65) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL1039187 0.83 NR1H2 (0.59) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL11994463 0.81 HDAC3 (0.53) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL1040640 0.80 HDAC3 (0.56) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL15299350 0.80 HDAC3 (0.60) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL5374900 0.80 MAP2K4 (0.47) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL13545717 0.79 NOTUM (0.52) HDAC3HDAC6NCOR2RAB9AIKBKB
SCHEMBL1436121 0.79 NR1H2 (0.61) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL9465116 0.78 NR1H2 (0.50) NR1H2NR1H3HDAC3HDAC6NCOR2
SCHEMBL16661177 0.78 HDAC3 (0.46) NR1H2NR1H3HDAC3HDAC6NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4169148-A Method of treating inflammatory and psychotic conditions with 1,2,4 triazole derivatives and compositions containing same E. R. SQUIBB & SONS, INC. (US) 1979-09-25 US claimed
US-7423036-B2 Long-acting betamimetics for the treatment of respiratory complaints BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-09-09 US disclosed
CN-1307282-C High molicular luminescent material of enery transfusion type poly(p-phenylene ethylene) like and it preparation process CHANGCHUN APPLIED CHEMISTRY (CN) 2007-03-28 CN disclosed
CN-1300195-C Energy-transfer poly(p-phenylene vinylene) polymer light-emitting materials and process for preparing same CHANGCHUN APPLIED CHEMISTRY (CN) 2007-02-14 CN disclosed
US-20060189607-A1 Long-acting betamimetics for the treatment of respiratory complaints BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-24 US disclosed
CN-1693415-A High molicular luminescent material of enery transfusion type poly(p-phenylene ethylene) like and it preparation process CHANGCHUN APPLIED CHEMISTRY (CN) 2005-11-09 CN disclosed
CN-1690095-A Energy-transfer poly(p-phenylene vinylene) polymer light-emitting materials and process for preparing same CHANGCHUN APPLIED CHEMISTRY (CN) 2005-11-02 CN disclosed
CN-1221580-C Energy transfer type poly (p-phenylene ethylene) high molecular luminescent material and preparation method thereof CHANGCHUN APPLIED CHEMISTRY (CN) 2005-10-05 CN disclosed
CN-1454962-A Energy transfer type poly (p-phenylene ethylene) high molecular luminescent material and preparation method thereof CHANG CHUN APPLIED CHEMISTRY I (CN) 2003-11-12 CN disclosed
US-4332812-A ANTIARTHRITIC E. R. SQUIBB & SONS, INC. (US) 1982-06-01 US disclosed
US-4169148-A Method of treating inflammatory and psychotic conditions with 1,2,4 triazole derivatives and compositions containing same E. R. SQUIBB & SONS, INC. (US) 1979-09-25 US disclosed
US-4127587-A ANTIINFLAMMATORY, ANTHELMINTIC E. R. SQUIBB & SONS, INC. (US) 1978-11-28 US disclosed
US-4093728-A ANTIINFLAMMATORY AGENTS, ANTHELMINTICS E. R. SQUIBB & SONS, INC. (US) 1978-06-06 US disclosed
US-4076823-A ANTIINFLAMMATORY, MUSCLE RELAXANT, ANXIOLYTIC, SEDATIVES E. R. SQUIBB & SONS, INC. (US) 1978-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189607-A1 Long-acting betamimetics for the treatment of respiratory complaints ADRA1A, ADRA1D, ADRA2A NR1H2 783/4885NR1H3 1068/4885HDAC3 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.